Branfield S, Somani Y, Washington A, Manfredi B
Curr Protoc. 2024; 4(7):e1095.
PMID: 39017668
PMC: 11331681.
DOI: 10.1002/cpz1.1095.
Ma L, Chen W, Pan Y, Yan H, Li H, Meng X
Aging (Albany NY). 2021; 13(6):8396-8407.
PMID: 33686963
PMC: 8034945.
DOI: 10.18632/aging.202650.
Wisniewski A
Medicina (Kaunas). 2021; 57(1).
PMID: 33435185
PMC: 7827369.
DOI: 10.3390/medicina57010059.
Slivka A, Rink C, Paoletto D, Sen C
FASEB J. 2020; 34(9):11838-11843.
PMID: 32686874
PMC: 7815323.
DOI: 10.1096/fj.201902216RR.
Pandey C, Misra A, Negi M, Kanuri B, Chhonker Y, Bhatta R
Indian J Med Res. 2019; 150(1):50-61.
PMID: 31571629
PMC: 6798616.
DOI: 10.4103/ijmr.IJMR_782_17.
Antiplatelet Agents in Secondary Stroke Prevention: Selection, Timing, and Dose.
Girotra T, Lowe F, Feng W, Ovbiagele B
Curr Treat Options Neurol. 2018; 20(8):32.
PMID: 29936577
DOI: 10.1007/s11940-018-0514-5.
Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study).
Le Calloch R, Lacut K, Le Gall-Ianotto C, Nowak E, Abiven M, Tempescul A
Haematologica. 2017; 103(4):607-613.
PMID: 29246923
PMC: 5865440.
DOI: 10.3324/haematol.2017.180448.
Obesity and Altered Aspirin Pharmacology.
Norgard N
Clin Pharmacokinet. 2017; 57(6):663-672.
PMID: 29139042
DOI: 10.1007/s40262-017-0611-8.
Interactions among -2, and variants are associated with aspirin responsiveness and adverse events in patients with ischemic stroke.
Yi X, Han Z, Zhou Q, Lin J, Wang C
Ther Adv Neurol Disord. 2017; 10(3):161-170.
PMID: 28344655
PMC: 5349374.
DOI: 10.1177/1756285616681943.
Interaction among COX-2, P2Y1 and GPIIIa gene variants is associated with aspirin resistance and early neurological deterioration in Chinese stroke patients.
Yi X, Wang C, Zhou Q, Lin J
BMC Neurol. 2017; 17(1):4.
PMID: 28068952
PMC: 5223580.
DOI: 10.1186/s12883-016-0788-8.
The lack of aspirin resistance in patients with coronary artery disease.
Homorodi N, Kovacs E, Lee S, Katona E, Shemirani A, Haramura G
J Transl Med. 2016; 14:74.
PMID: 26980433
PMC: 4793490.
DOI: 10.1186/s12967-016-0827-7.
Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents.
Parekh P, Oldfield 4th E, Johnson D
Drugs. 2015; 75(14):1613-25.
PMID: 26330139
DOI: 10.1007/s40265-015-0455-1.
Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy.
Timur A, Murugesan G, Zhang L, Barnard J, Bhatt D, Kottke-Marchant K
Thromb Res. 2014; 134(1):96-104.
PMID: 24852729
PMC: 4097303.
DOI: 10.1016/j.thromres.2014.04.023.
Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes.
Thomas M, Storey R
J Cardiovasc Transl Res. 2013; 7(1):19-28.
PMID: 24309957
DOI: 10.1007/s12265-013-9524-6.
Aspirin resistance: a clinical review focused on the most common cause, noncompliance.
Schwartz K
Neurohospitalist. 2013; 1(2):94-103.
PMID: 23983843
PMC: 3726079.
DOI: 10.1177/1941875210395776.
Aspirin treatment failure: is this a real phenomenon? A review of the aetiology and how to treat it.
Shahid F, Chahal C, Akhtar M
JRSM Short Rep. 2013; 4(4):30.
PMID: 23560230
PMC: 3616305.
DOI: 10.1177/2042533313475576.
Protocol for a systematic review of the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease.
Raichand S, Moore D, Riley R, Lordkipanidze M, Dretzke J, ODonnell J
Syst Rev. 2013; 2:16.
PMID: 23442317
PMC: 3600664.
DOI: 10.1186/2046-4053-2-16.
Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin.
Grosser T, Fries S, Lawson J, Kapoor S, Grant G, FitzGerald G
Circulation. 2012; 127(3):377-85.
PMID: 23212718
PMC: 3552520.
DOI: 10.1161/CIRCULATIONAHA.112.117283.
Aspirin resistance: current status and role of tailored therapy.
Grinstein J, Cannon C
Clin Cardiol. 2012; 35(11):673-81.
PMID: 22740110
PMC: 6652698.
DOI: 10.1002/clc.22031.
Measurement of platelet reactivity of patients with cardiovascular disease on-treatment with acetyl salicylic acid: a prospective study.
Awidi A, Saleh A, Dweik M, Kailani B, Abu-Fara M, Nabulsi R
Heart Vessels. 2010; 26(5):516-22.
PMID: 21181173
DOI: 10.1007/s00380-010-0086-0.